Video: Novel Targeted Antioxidants Therapy Takes Aim at Breast Cancer
Balaraman Kalyanaraman, PhD, Harry R. & Angeline E. Quadracci Professor in Parkinson's Research and chairman of biophysics, is the principal investigator. He received a five-year, $1.5 million grant from the National Institutes of Health's Cancer Institute to develop targeted therapies to enhance the killing power of anti-cancer while simultaneously protecting the heart from the drug's toxic side effects.
"One of the challenges of cancer therapy is to kill tumor cells while simultaneously minimizing the drug's side effects", said Dr. Kalyanaraman, "Novel targeted antioxidant therapy is doing just that."
Novel Targeted Antioxidants Take Aim at Enhancing Breast Cancer Therapy, While Reducing Side Effects
For additional information, please contact Media Relations at (414) 955-4700 or via email at firstname.lastname@example.org